P2‐476: A Phase 1, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral daily doses of ELND006 in healthy elderly subjects
Liang E, Liu W, Lohr L, Nguyen V, Lin H, Munson M, Crans G, Cedarbaum J. P2‐476: A Phase 1, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral daily doses of ELND006 in healthy elderly subjects. Alzheimer's & Dementia 2011, 7: s465-s465. DOI: 10.1016/j.jalz.2011.05.1347.Peer-Reviewed Original Research